[Pegvisomant decreases growth hormone to nothing].

Suppr

超能文献

出版信息

Krankenpfl J. 2004;42(1-2):16-7.

PMID:15116768

Abstract

摘要

相似文献

[Pegvisomant decreases growth hormone to nothing].

Krankenpfl J. 2004;42(1-2):16-7.

[Drug therapy of acromegaly].

Krankenpfl J. 2004;42(7-10):260-1.

Treatment of acromegaly.

N Engl J Med. 2000 Apr 20;342(16):1210-1. doi: 10.1056/NEJM200004203421611.

Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

N Engl J Med. 2000 Apr 20;342(16):1171-7. doi: 10.1056/NEJM200004203421604.

[Growth hormone-receptor antagonist pegvisomant].

Dtsch Med Wochenschr. 2004 Oct 29;129(44):2356-8. doi: 10.1055/s-2004-835268.

Growth hormone receptor antagonists.

Neuroendocrinology. 2006;83(3-4):264-8. doi: 10.1159/000095537. Epub 2006 Oct 13.

Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.

Eur J Endocrinol. 2005 Jan;152(1):47-51. doi: 10.1530/eje.1.01822.

Pegvisomant (Somavert) for acromegaly.

Med Lett Drugs Ther. 2003 Jul 7;45(1160):55-6.

Place of pegvisomant in acromegaly.

Lancet. 2001 Nov 24;358(9295):1743-4. doi: 10.1016/S0140-6736(01)06839-8.

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

J Clin Endocrinol Metab. 2001 Feb;86(2):478-81. doi: 10.1210/jcem.86.2.7206.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Pegvisomant decreases growth hormone to nothing].

Krankenpfl J. 2004;42(1-2):16-7.

[Drug therapy of acromegaly].

Krankenpfl J. 2004;42(7-10):260-1.

Treatment of acromegaly.

N Engl J Med. 2000 Apr 20;342(16):1210-1. doi: 10.1056/NEJM200004203421611.

Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant.

N Engl J Med. 2000 Apr 20;342(16):1171-7. doi: 10.1056/NEJM200004203421604.

[Growth hormone-receptor antagonist pegvisomant].

Dtsch Med Wochenschr. 2004 Oct 29;129(44):2356-8. doi: 10.1055/s-2004-835268.

Growth hormone receptor antagonists.

Neuroendocrinology. 2006;83(3-4):264-8. doi: 10.1159/000095537. Epub 2006 Oct 13.

Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.

Eur J Endocrinol. 2005 Jan;152(1):47-51. doi: 10.1530/eje.1.01822.

Pegvisomant (Somavert) for acromegaly.

Med Lett Drugs Ther. 2003 Jul 7;45(1160):55-6.

Place of pegvisomant in acromegaly.

Lancet. 2001 Nov 24;358(9295):1743-4. doi: 10.1016/S0140-6736(01)06839-8.

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

J Clin Endocrinol Metab. 2001 Feb;86(2):478-81. doi: 10.1210/jcem.86.2.7206.